CU20110036A7 - DRUG ADMINISTRATION SYSTEM CONTAINING PROGESTINE - Google Patents
DRUG ADMINISTRATION SYSTEM CONTAINING PROGESTINEInfo
- Publication number
- CU20110036A7 CU20110036A7 CU20110036A CU20110036A CU20110036A7 CU 20110036 A7 CU20110036 A7 CU 20110036A7 CU 20110036 A CU20110036 A CU 20110036A CU 20110036 A CU20110036 A CU 20110036A CU 20110036 A7 CU20110036 A7 CU 20110036A7
- Authority
- CU
- Cuba
- Prior art keywords
- progestin
- progestine
- drug administration
- system containing
- administration system
- Prior art date
Links
- 239000000583 progesterone congener Substances 0.000 title abstract 5
- 238000001647 drug administration Methods 0.000 title 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 4
- 239000003223 protective agent Substances 0.000 abstract 2
- 238000012377 drug delivery Methods 0.000 abstract 1
- 230000000873 masking effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 235000012431 wafers Nutrition 0.000 abstract 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Composiciones de administración de drogas en forma de películas delgadas solubles en agua (obleas), que contienen partículas que comprenden al menos una progestina y al menos un agente protector. El agente protector provee el enmascaramiento efectivo del sabor de la progestina debido a la liberación limitada de la progestina en la boca. Por consiguiente, la progestina no es absorbida a través de la ruta bucal, sino que lo es a través de la ruta entérica (peronal).Drug delivery compositions in the form of thin water-soluble films (wafers), which contain particles comprising at least one progestin and at least one protective agent. The protective agent provides effective masking of the taste of progestin due to the limited release of progestin in the mouth. Therefore, progestin is not absorbed through the buccal route, but is absorbed through the enteric (peronal) route.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8733408P | 2008-08-08 | 2008-08-08 | |
| EP08162105 | 2008-08-08 | ||
| EP09900094 | 2009-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20110036A7 true CU20110036A7 (en) | 2012-06-21 |
Family
ID=46515002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU20110036A CU20110036A7 (en) | 2008-08-08 | 2011-02-08 | DRUG ADMINISTRATION SYSTEM CONTAINING PROGESTINE |
Country Status (1)
| Country | Link |
|---|---|
| CU (1) | CU20110036A7 (en) |
-
2011
- 2011-02-08 CU CU20110036A patent/CU20110036A7/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP11010815A (en) | DRUG ADMINISTRATION SYSTEM CONTAINING PROGESTINE | |
| WO2014130866A3 (en) | Targeted buccal delivery comprising cisplatin-loaded chitosan nanoparticles | |
| PE20091574A1 (en) | DRUG ADMINISTRATION SYSTEM WITH STABILIZING EFFECT | |
| MX2009000745A (en) | Transmucosal delivery devices with enhanced uptake. | |
| MX2010003642A (en) | Vaccine nanotechnology. | |
| AR078417A1 (en) | SUBLINGUAL AND BUCAL FILM COMPOSITIONS | |
| UY31957A (en) | IMPROVED ANTI-CONCEPTIVE METHOD | |
| CY1119140T1 (en) | COMPOSITION COMPOSITIONS AND METHODS OF CONSTRUCTION AND USE | |
| WO2012079092A3 (en) | Testosterone undecanoate compositions | |
| CL2012001080A1 (en) | Rifaximin solid dispersion and a pharmaceutically acceptable carrier; pharmaceutical composition; use in the treatment and / or prevention of a microbial infection comprising the administration of the solid dispersion. | |
| MX2009012858A (en) | VACCINE FOR THE PREVENTION OF BREAST OF CANCER OF SENO. | |
| ATE474564T1 (en) | SMALL VOLUME, ORAL, TRANSMUCOSAL DOSAGE FORMS OF SUFENTANIL FOR PAIN TREATMENT | |
| NZ707377A (en) | Combination therapy methods for treating proliferative diseases | |
| AR089509A1 (en) | METHOD FOR TREATING LOSS OSEA ALVEOLAR, A DENTAL IMPLANT, AN ANTIBODYCEROSTIN ANTIBODY, A GEL OR MATRIX THAT INCLUDES SUCH ANTIBODY AND USE | |
| MX337723B (en) | IgE CH3 PEPTIDE VACCINE. | |
| CO7101247A2 (en) | Polyinosinic-polycytidyl acid (poly (i: c)) formulations for the treatment of upper respiratory infections | |
| BR112018068642A2 (en) | composition and use of composition | |
| MX2015007678A (en) | Transmucosal delivery of glatiramer acetate. | |
| MX365216B (en) | Quick dissolving diphenhydramine oral dosage form. | |
| NZ601890A (en) | Treatment or prevention of infection | |
| PE20130147A1 (en) | PHARMACEUTICAL COMBINATION OF THEOBROMINE AND A NON-OPIOID ANTITUSSIVE AGENT | |
| PH12015502274B1 (en) | Lozenge for treating a sore throat, hoarseness, and associated dry cough and for treating inflammatory diseases of the oral cavity and of the pharynx | |
| MX2015007794A (en) | Oral transmucosal delivery of glatiramer acetate. | |
| MX375187B (en) | DRY PHARMACEUTICAL COMPOSITIONS COMPRISING NANOPARTICLES OF ACTIVE AGENT LINKED TO CARRIER PARTICLES. | |
| CR11632A (en) | DRUG ADMINISTRATION SYSTEM CONTAINING ESTRADIOL |